ClinicalTrials.gg
Drug

Paricalcitol clinical trials

Also written Zemplar, ABT-358 and Compound 49510.

studies test it
91
open now
2
in phase 3
20
first study started
2002

How each study uses paricalcitol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the paricalcitol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Apr 1998 · ZEMPLAR · NDA 020819 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Paricalcitol
71
Zemplar (paricalcitol injection)
3
Paricalcitol injection
3

Brand

Zemplar
46

Development codes

ABT-358
15
Compound 49510
2

Studies by the year they started

91 studies that test it; most in 2009 (14)

Studies that test paricalcitol, by start year
YearStudies
20025
20033
20044
20053
20065
20076
20088
200914
201010
20114
20127
20131
20144
20151
20161
20173
20183
20191
20203
20211
20221
20231
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
10
Phase 2
22
Phase 3
20
Phase 4
27
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 33 · Other 58

Abbott (21) · AbbVie (prior sponsor, Abbott) (5) · Wake Forest University Health Sciences (3) · Cedars-Sinai Medical Center (2) · HonorHealth Research Institute (2) · Abramson Cancer Center at Penn Medicine (2) · Washington University School of Medicine (2) · Mario Negri Institute for Pharmacological Research (2)

Often tested with

Tested in the same studies.

Calcitriol (6) · Gemcitabine (4) · 1 alpha-hydroxyergocalciferol (3) · Hydroxychloroquine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Cholecalciferol (2) · Losartan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test paricalcitol.

Studies

Open first, then newest update. How each study uses paricalcitol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 91

See all 91 studies that test paricalcitol →

Given beside what is tested · 2 — paricalcitol is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with paricalcitol

Codes

What other systems call paricalcitol · ClinicalTrials.gg INT003762

  • MeSH (NLM) C084656paricalcitolConfirmed NLM, Wikidata
  • UNII (FDA) 6702D36OG5PARICALCITOLConfirmed FDA, NLM, Wikidata
  • RxNorm 73710Confirmed FDA, Wikidata
  • Wikidata Q155746paricalcitolConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C38693ParicalcitolOne source FDA
  • DrugBank DB00910One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.